Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.prnewswire.com/news-releases/iterum-therapeutics-announces-positive-topline-results-from-its-phase-3-reassure-clinical-trial-of-oral-sulopenem-in-uncomplicated-urinary-tract-infections-302047483.html
https://www.globenewswire.com/news-release/2023/01/11/2587531/0/en/Iterum-Therapeutics-Reports-Employment-Inducement-Grant.html
https://www.globenewswire.com/news-release/2022/12/15/2574503/0/en/Iterum-Therapeutics-announces-Issuance-of-Allowance-for-a-U-S-Patent-Covering-Oral-Sulopenem.html
https://www.globenewswire.com/news-release/2022/11/10/2552987/0/en/Iterum-Therapeutics-Reports-Third-Quarter-2022-Financial-Results.html
https://www.globenewswire.com/news-release/2022/11/03/2547570/0/en/Iterum-Therapeutics-to-Provide-Business-Update-and-Report-Third-Quarter-2022-Financial-Results-on-November-10-2022.html
https://www.globenewswire.com/news-release/2022/10/20/2538209/0/en/Iterum-Announces-First-Patient-Dosed-in-REASSURE-a-Phase-3-Clinical-Trial-of-Oral-Sulopenem-in-Uncomplicated-Urinary-Tract-Infections.html
https://www.globenewswire.com/news-release/2022/10/17/2535928/0/en/Iterum-Therapeutics-to-Present-Data-at-IDWeek-2022.html
https://www.globenewswire.com/news-release/2022/09/19/2518199/0/en/Iterum-Therapeutics-announces-Issuance-of-Allowance-for-a-U-S-Patent-Covering-Oral-Sulopenem.html
https://www.globenewswire.com/news-release/2022/09/07/2511680/0/en/Iterum-Therapeutics-to-Present-at-the-H-C-Wainwright-24th-Annual-Global-Investment-Conference.html
https://www.globenewswire.com/news-release/2022/09/01/2508943/0/en/Iterum-Therapeutics-Regains-Compliance-with-Nasdaq-Bid-Price-Rule.html